CareFusion PT Raised to $48.00 (CFN)
Stock analysts at JPMorgan Chase & Co. boosted their target price on shares of CareFusion (NYSE:CFN) from $44.00 to $48.00 in a report issued on Friday. JPMorgan Chase & Co.’s target price would indicate a potential upside of 12.97% from the stock’s previous close.
CareFusion (NYSE:CFN) opened at 42.49 on Friday. CareFusion has a 52-week low of $35.01 and a 52-week high of $45.81. The stock’s 50-day moving average is $44.32 and its 200-day moving average is $41.65. The company has a market cap of $8.809 billion and a price-to-earnings ratio of 23.55.
CareFusion (NYSE:CFN) last announced its earnings results on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.72 by $0.07. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the company posted $0.55 earnings per share. CareFusion’s revenue was up 24.3% compared to the same quarter last year. Analysts expect that CareFusion will post $2.68 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at BMO Capital Markets raised their price target on shares of CareFusion from $46.00 to $48.00 in a research note on Friday. Separately, analysts at Stifel Nicolaus raised their price target on shares of CareFusion from $42.00 to $49.00 in a research note on Friday. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of CareFusion in a research note on Thursday, July 31st. They now have a $47.00 price target on the stock. Five research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. CareFusion currently has an average rating of “Buy” and an average price target of $45.17.
CareFusion Corporation (NYSE:CFN) is a global medical technology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.